>>> US Gapping Up

Gapping up
In reaction to strong earnings/guidance: QTM +13.7%, SWKS +7.6%, DFRG +7%, DPZ +3%, TC +2.6%, JNJ +1.4%, C +1.1%, HSON +0.5%

M&A news: CSX +0.9% (WSJ discusses that Canadian Pacific (CP) merger with CSX is still possible, while Reuters piece is cautious on the merger, initiated with a Buy at UBS)

Select Ebola related names showing strength: NLNK +8.3%, NNVC +5%, INO +4.6%, HEB +2.7%, SRPT +1.5%

Other news: SMED +8.1% (cont vol), GALE +7% (receives notice of allowance of improvement patent for NeuVax (nelipepimut-S) in Japan), LAKE +6.9% (following 45% move higher yesterday with ongoing Ebola concerns), APT +5.8% (following 35% move higher yesterday with ongoing Ebola concerns), PBMD +5.1% (disclosed that Immutep received a Notice of Allowance from Australian Patent Office for Patent Application AU 2008306576), HZNP +4.9% (co reviewed opportunities for ACTIMMUNE: potential for $500 mln or greater in peak annual sales if approved by the FDA for Friedreich's Ataxia), SUNE +4% (amends letter of credit facility to $800 mln USD for credit commitments and future increases), JRJC +2.6% (releases enhanced mobile application), MBLY +2.1% (still checking), MU +1.9% (Samsung Elect CEO downplayed fears of increased competition in chip space after co last week announced plans for new factory, which took down Micron last wk), RIO +1.8% (may be in sympathy after BHP upgrade), SDRL +1.5% (still checking), DRYS +1.4% (modest pull back following yest's 17% slide), YHOO +1.4% (may be related to Alibaba (BABA) upgrade),PCRX +1.1% (announces additional data supporting safety of EXPAREL in peripheral nerve block)

Analyst comments: BHP +1.9% (upgraded to Neutral from Underperform at Credit Suisse), ETN +1.3% (upgraded to Overweight from Equal Weight at Barclays), VOD +0.8% (initiated with a Buy at Deutsche Bank), EOG +0.7% (upgraded to Outperform from Mkt Perform at Bernstein), AAPL +0.7% (target raised to $110 from $96 at Credit Suisse
)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance: WWW -2.6%, UEC -0.9%, JPM -0.8%, NEPT -0.6%, EXAC -0.4%, WFC -0.4%

Other news: NSPH -22.8% (pulling back after yest's 78% advance), CDXS -4.8% (late move higher on speculation of name as Ebola play), EXAS -3.3% (modest pullback following recent advance), AMD -2.6% (not seeing any catalysts to directly account for the move; heavy put volume observed during today's session), MGM -1.1% (may be in sympathy with peers LVS and WYNN dg's),SHPG -0.9% (may be related to Ireland tax rule changes), SIG -0.8% (CEO resigns from co)

Analyst comments: WYNN -1.6% (downgraded to Neutral from Buy at BofA/Merrill), CI -0.8% (downgraded to Neutral from Buy at Sterne Agee), TYC -0.7% (downgraded to Equal Weight from Overweight at Barclays), GT -0.6% (target lowered to $31 from $36 at Goldman; removed from Conviction Buy list), LVS -0.6% (downgraded to Neutral from Buy at BofA/Merrill), FAST -0.6% (downgraded to Neutral from Positive at Susquehanna), JCI -0.5% (downgraded to Market Perform from Outperform at Wells Fargo), ENOC -0.5% (downgraded to Neutral from Overweight at JP Morgan), LEA -0.5% (downgraded to Neutral from Buy at Goldman), HD -0.4% (downgraded to Neutral from Buy at Sun Trust Rbsn Humphrey)

(BFW) Airbus CEO Disparages German Defense Policy in Cicero Interview

Airbus CEO Disparages German Defense Policy in Cicero Interview
2014-10-14 12:25:27.148 GMT


By Richard Weiss
Oct. 14 (Bloomberg) -- German defense capabilities as they
stand are the results of years of “dishonest” dealing between
defense industry and government, Airbus CEO Thomas Enders says
in excerpt of interview with Cicero magazine to be published on
Oct. 23.
* Airbus incurred EU4b in losses with A400M project; co.
wouldn’t sign such a contract with unrealistic budget and
time-line again
* Germany should put words to action when it comes to defense
capabilities, increase defense spending
* Defense ministry not talking enough to military end-users
* German Defense Ministry Sets Conditions for A400M:
Handelsblatt
* NOTE: Germany’s New Foreign Policy Means Same Old Reluctance
to Fight


For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Richard Weiss in Frankfurt at +49-69-92041-287 or
rweiss5@bloomberg.net
To contact the editor responsible for this story:
Benedikt Kammel at +49-30-70010-6230 or
bkammel@bloomberg.net

>>> JNJ beats by $0.06, reports revs in-line; raises FY14 EPS above consensus

--> JNJ +1.47% Pre-Open 16k traded

Johnson & Johnson beats by $0.06, reports revs in-line; raises FY14 EPS above consensus

Reports Q3 (Sep) earnings of $1.50 per share, $0.06 better than the Capital IQ Consensus of $1.44; revenues rose 5.1% year/year to $18.47 bln vs the $18.41 bln consensus.
  • Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%.
  • During the quarter the Company completed the divestiture of the Ortho-Clinical Diagnostics business. Worldwide, domestic and international operational sales growth, excluding the impact of this divestiture, was 8.4%; 14.8% and 3.1% respectively.
Co issues upside guidance for FY14, raises EPS to $5.92-5.97 from $5.85-5.92 vs. $5.92 Capital IQ Consensus.
  • Worldwide Consumer sales of $3.6 billion for the third quarter represented a decrease of 0.6% versus the prior year consisting of an operational increase of 0.3% and a negative impact from currency of 0.9%.
  • Worldwide Pharmaceutical sales of $8.3 billion for the third quarter represented an increase of 18.1% versus the prior year with operational growth of 18.7% and a negative impact from currency of 0.6%.
  • Worldwide Medical Devices and Diagnostics sales of $6.6 billion for the third quarter represented a decrease of 5.2% versus the prior year consisting of an operational decrease of 4.6% and a negative currency impact of 0.6%.

>>> Domino's Pizza beats by $0.02, beats on revs

Domino's Pizza beats by $0.02, beats on revs

Reports Q3 (Sep) earnings of $0.63 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus Estimate of $0.61; revenues rose 10.5% year/year to $446.6 mln vs the $434.06 mln consensus, due primarily to higher supply chain revenues from increased volumes in the supply chain centers and elevated commodity prices, specifically cheese, as well as increased sales of equipment and supplies to stores as our store reimaging program accelerates.
  • Domestic comps +7.7%; International +7.1% (ex-FX)
  • Additionally, sales and store growth contributed to increased revenues in all business segments.
  • During Q3, the Company repurchased and retired 242,700 shares of its common stock under its open market share repurchase program for ~$17.4 million, or an average price of $71.69 per share.